Unit 1 Exam Pharmacology Comprehensive
Questions And Correct Answers
1. A client tells the nurse, "I have been reading about research trials, and would
like to be involved in one." The nurse asks the client if she has any documented
diseases, knowing the client might be eligible to participate in which clinical
trial phase?
a. Phase I
b. Phase II
c. Preclinical investigation
d. Postmarketing surveillance: b. Phase II
2. 2.
A client who plans to purchase drugs from Canada expresses concern that the
drugs will be substandard. The nurse explains:
a. "You should have reservations about obtaining drugs from Canada."
b. "Drugs from Canada must comply with standards established by recognized
formularies in the United States and are safe."
c. "The Canadian Food and Drug Act has a much different approval process
that is not as stringent as ours in the United States."
d. "I can understand you want to save money, but it would be better to
purchase your drugs in the United States.": b. "Drugs from Canada must comply with standards
established by recognized formularies in the United States and are safe."
3. A client prefers to purchase over-the-counter medications rather than pre-
scription medications whenever possible. The nurse informs the client that
advantages to using over-the-counter (OTC) medications include which of the
following?
a. They are less expensive than prescription medications.
b. Fewer side effects can be expected.
c. Access to them is easier.
,d. They do not interact with food and beverages.: c. Access to them is easier.
4. The nurse explains to a client that the phase postmarketing surveillance is
best described as:
, a. Trials and animal drug testing
b. The longest part of the approval process
c. The final stage of the approval process
d. Extensive laboratory research: c. The final stage of the approval process
5. The nurse explains to a client that during the FDA drug approval process,
clinical investigators from many different medical specialties address con-
cerns such as:
a. Whether the drug is effective.
b. Whether a New Drug Application (NDA) must be filed.
c. Placing the application for review for six months.
d. Determining the marketability of the drug.: a. Whether the drug is ettective.
6. A client asks the nurse, "I read that the pill I am taking is a biologic. Is
this some kind of special drug?" The nurse's explanation is based on the
knowledge that biologics:
a. Include medications as well as all types of complementary alternative
therapies.
b. Are strictly derived from natural plant products.
c. Are drugs that are similar to natural products but are artificially created in
a laboratory.
d. Are agents naturally produced by animals, microorganisms, or the human
body.: d. Are agents naturally produced by animals, microorganisms, or the human body.
7. A healthy, young client informs the nurse that she has enrolled in a clinical
drug research study. The nurse recognizes that the client is involved in which
phase of trials?
a. Preclinical investigation
b. Clinical investigation
c. Review of the New Drug Application (NDA)
d. Postmarketing surveillance: b. Clinical investigation
Questions And Correct Answers
1. A client tells the nurse, "I have been reading about research trials, and would
like to be involved in one." The nurse asks the client if she has any documented
diseases, knowing the client might be eligible to participate in which clinical
trial phase?
a. Phase I
b. Phase II
c. Preclinical investigation
d. Postmarketing surveillance: b. Phase II
2. 2.
A client who plans to purchase drugs from Canada expresses concern that the
drugs will be substandard. The nurse explains:
a. "You should have reservations about obtaining drugs from Canada."
b. "Drugs from Canada must comply with standards established by recognized
formularies in the United States and are safe."
c. "The Canadian Food and Drug Act has a much different approval process
that is not as stringent as ours in the United States."
d. "I can understand you want to save money, but it would be better to
purchase your drugs in the United States.": b. "Drugs from Canada must comply with standards
established by recognized formularies in the United States and are safe."
3. A client prefers to purchase over-the-counter medications rather than pre-
scription medications whenever possible. The nurse informs the client that
advantages to using over-the-counter (OTC) medications include which of the
following?
a. They are less expensive than prescription medications.
b. Fewer side effects can be expected.
c. Access to them is easier.
,d. They do not interact with food and beverages.: c. Access to them is easier.
4. The nurse explains to a client that the phase postmarketing surveillance is
best described as:
, a. Trials and animal drug testing
b. The longest part of the approval process
c. The final stage of the approval process
d. Extensive laboratory research: c. The final stage of the approval process
5. The nurse explains to a client that during the FDA drug approval process,
clinical investigators from many different medical specialties address con-
cerns such as:
a. Whether the drug is effective.
b. Whether a New Drug Application (NDA) must be filed.
c. Placing the application for review for six months.
d. Determining the marketability of the drug.: a. Whether the drug is ettective.
6. A client asks the nurse, "I read that the pill I am taking is a biologic. Is
this some kind of special drug?" The nurse's explanation is based on the
knowledge that biologics:
a. Include medications as well as all types of complementary alternative
therapies.
b. Are strictly derived from natural plant products.
c. Are drugs that are similar to natural products but are artificially created in
a laboratory.
d. Are agents naturally produced by animals, microorganisms, or the human
body.: d. Are agents naturally produced by animals, microorganisms, or the human body.
7. A healthy, young client informs the nurse that she has enrolled in a clinical
drug research study. The nurse recognizes that the client is involved in which
phase of trials?
a. Preclinical investigation
b. Clinical investigation
c. Review of the New Drug Application (NDA)
d. Postmarketing surveillance: b. Clinical investigation
